Vietnam Diagnostic Tests Market Research Report: Forecast (2026-2032)

Vietnam Diagnostic Tests Market Key Takeaways

• The Vietnam Diagnostic Tests Market is valued at USD 1.68 billion in 2025 and is projected to reach USD 1.91 billion by 2026 and USD 3.13 billion by 2032.
• The industry is projected to witness steady growth at a CAGR of 8.59% during 2026–2032.
• Immunoassay-Based Diagnostic Tests lead the market by test technology, accounting for approximately 30% of total market revenue in 2026.
• Infectious Diseases represent the largest disease application segment, contributing approximately 32% of the market in 2026.
• The market remains moderately fragmented, with the top five companies accounting for approximately 39% of total market share in 2026.

Vietnam Diagnostic Tests Market Size & Outlook

The Vietnam Diagnostic Tests Market was valued at USD 1.68 Billion in 2025 and is projected to reach USD 1.91 Billion in 2026 and USD 3.13 Billion by 2032, expanding at a CAGR of 8.59% during 2026–2032.

Market growth is being supported by the rising burden of chronic and infectious diseases, increasing healthcare investments, and expanding access to healthcare services across the country. Growing emphasis on preventive healthcare and early disease identification is encouraging greater utilization of diagnostic screening solutions across hospitals, laboratories, and outpatient care settings.

Vietnam’s changing disease landscape continues to create strong demand for testing services. In 2025, the country recorded 181,200 dengue cases and 43 deaths in 2025, representing a 33% increase in cases and 17 additional deaths compared with 2024. The increasing need for disease monitoring, risk assessment, and treatment management is driving testing volumes nationwide. These healthcare trends are supporting the expansion of the medical diagnostics industry and encouraging healthcare providers to strengthen their diagnostic capabilities through advanced testing technologies.

The market is also benefiting from healthcare modernization initiatives and rapid digital transformation. The implementation of the Law on Medical Examination and Treatment (2024) and the expansion of electronic medical records are improving healthcare connectivity and patient data management. At the same time, hospitals and laboratories are investing in automation technologies, advanced imaging equipment, and molecular testing platforms to improve efficiency and diagnostic accuracy. These developments are accelerating the adoption of healthcare testing technologies throughout Vietnam’s healthcare ecosystem.

Furthermore, increasing investments by multinational diagnostic companies and healthcare institutions are enhancing the country's testing infrastructure. The deployment of artificial intelligence-enabled imaging systems, automated laboratory workflows, and advanced molecular diagnostic platforms is improving service quality and operational efficiency. While infrastructure disparities remain in some provincial regions, continued government support and technology adoption are expected to create favorable conditions for long-term market growth and further expansion of Vietnam’s diagnostic testing industry.

Vietnam Diagnostic Tests Market Key Indicators

• According to the WHO Global Tuberculosis Report 2024, Vietnam recorded over 113,000 tuberculosis cases in 2024, with an estimated incidence rate of around 182 cases per 100,000 population, placing the country among high TB-burden nations. This persistent TB prevalence is driving strong demand for molecular diagnostic testing solutions and strengthening infectious disease diagnostics capacity across Vietnam’s healthcare system.
• According to the U.S. International Trade Administration (2025), Vietnam’s medical device market was valued at approximately USD 1.9 billion in 2024, with around 90% of medical equipment supplied through imports. The large installed base of imported medical technologies, including diagnostic and laboratory equipment, highlights the country’s increasing reliance on advanced testing infrastructure and modernization of healthcare facilities.
• According to the Ministry of Health of Vietnam, cited by Vietnam Briefing (2025), the domestic medical equipment market reached nearly USD 1.7 billion in 2024 and has maintained strong growth driven by healthcare modernization initiatives. Continued investments in hospital equipment, laboratory systems, and healthcare infrastructure create a favourable environment for the expansion of diagnostic capabilities nationwide.
• According to the International Agency for Research on Cancer (IARC), Vietnam recorded 180,480 new cancer cases in the latest available national assessment. The growing burden of oncology cases requires extensive use of screening, pathology, molecular testing, and disease-monitoring services, increasing the demand for diagnostic procedures across the care continuum.
• According to Vietnam’s Ministry of Health surveillance data (2024–2025), the country continues to report a high burden of infectious diseases, including dengue fever, measles, and hand, foot, and mouth disease. Dengue cases exceeded 200,000 in 2025, while over 70,000 hand, foot, and mouth disease cases were recorded in 2024, highlighting persistent outbreak cycles. This sustained disease burden is increasing demand for diagnostic screening solutions and strengthening clinical diagnostics capacity across Vietnam’s healthcare system

Vietnam Diagnostic Tests Market Scope

Vietnam Diagnostic Tests Market Drivers

Increasing Prevalence of Chronic Diseases Driving Demand for Diagnostic Testing Services

The Vietnam Diagnostic Tests Market is experiencing strong growth due to the increasing prevalence of chronic diseases, which is driving the need for early detection, disease monitoring, and preventive healthcare services. According to the International Diabetes Federation, approximately 7 million individuals were living with diabetes in Vietnam in 2024, while the Vietnam National Heart Association estimates that nearly 12 million people suffer from hypertension. The growing burden of cardiovascular disorders, metabolic diseases, chronic kidney disease, and liver-related conditions continues to increase the volume of routine testing and follow-up monitoring conducted across healthcare facilities nationwide.

The rising incidence of cancer in Vietnam is significantly increasing demand for advanced diagnostic procedures such as pathology testing, biomarker analysis, and molecular diagnostics. In addition, cardiovascular diseases remain the leading cause of mortality, accounting for nearly 30% of total deaths annually, highlighting the growing clinical need for continuous monitoring and early detection. Furthermore, chronic kidney disease affects around 12% of the population as of 2024, reinforcing the importance of timely and accurate diagnostic evaluation for effective treatment planning. Collectively, the increasing burden of chronic and age-related diseases is driving the expansion of diagnostic screening solutions and strengthening the adoption of clinical diagnostics across Vietnam’s healthcare system.

Recent Trends

Expanding Digital Health Adoption and AI Integration Reshaping Diagnostic Services

The Vietnam Diagnostic Tests Market is increasingly influenced by the country’s ongoing healthcare digitalization efforts. According to the World Bank, 84% of Vietnam’s population used the internet in 2024, creating a favorable environment for technology-enabled healthcare services. The government continues to promote electronic medical records and digital hospital systems, encouraging healthcare providers to modernize clinical workflows. As a result, the adoption of digital healthcare solutions is improving operational efficiency and supporting faster access to diagnostic services across healthcare facilities.

Artificial intelligence is also emerging as a key trend in Vietnam’s healthcare sector. In December 2024, VinBrain launched DrAid EndoAI, an AI-powered endoscopy platform trained on nearly 500,000 annotated endoscopic images and capable of detecting five gastrointestinal lesion types with up to 95.9% accuracy. Reflecting the growing adoption of advanced diagnostic technologies in clinical practice. The increasing utilization of AI-powered diagnostics and technology-enabled healthcare platforms is enhancing diagnostic accuracy, reducing turnaround times, and supporting the modernization of healthcare infrastructure across Vietnam.

Vietnam Diagnostic Tests Market Opportunities and Challenges

Uneven Healthcare Infrastructure Creating Opportunities Through Government-Led Healthcare Modernization

Despite continuous healthcare investments, access to advanced diagnostic services remains uneven across Vietnam, particularly in provincial and rural areas. Many lower-tier healthcare facilities face limitations in laboratory capacity, skilled personnel, and specialized equipment, restricting complex testing availability. High capital costs, including nearly USD 3 million for MRI systems, further slow adoption. In addition, testing expenses such as USD 50 for PCR and up to USD 300 for biopsy procedures create affordability barriers. These factors limit penetration of diagnostic testing services and widen gaps in clinical diagnostics access across the country.

This infrastructure gap is simultaneously creating significant opportunities for market expansion. The implementation of the Law on Medical Examination and Treatment in 2024 and Circular 38/2024/TT-BYT is accelerating healthcare digitalization and strengthening nationwide healthcare connectivity. These initiatives support investments in laboratory modernization, regional testing capacity, and healthcare technology upgrades. As healthcare providers expand access to advanced diagnostic technologies and modern laboratory systems, market participants are expected to benefit from rising demand for efficient and accessible diagnostic solutions throughout Vietnam.

Vietnam Diagnostic Tests Market Segmentation

Immunoassay-Based Diagnostic Tests Dominated the Vietnam Diagnostic Tests Market

Immunoassay-based diagnostic tests accounted for an estimated 30% share of the Vietnam Diagnostic Tests Market in 2026, making them the largest technology segment. Their dominance is driven by high accuracy, rapid turnaround times, and broad applicability across infectious disease, hormone, and chronic disease testing. These advantages have made immunoassays a preferred choice among hospitals and laboratories. The widespread use of this technology continues to support growth within the diagnostic testing market and strengthen demand for routine screening services.

The segment also benefits from its affordability and accessibility compared to many advanced testing methods. For instance, SARS-CoV-2 antigen tests have been available at approximately USD 7–8 per test, enabling wider adoption among patients and healthcare providers. Immunoassays are extensively used for hepatitis B, hepatitis C, HIV, and tuberculosis screening, where rapid diagnosis is essential for timely treatment. Their cost efficiency and scalability continue to support adoption across the clinical diagnostics sector and expand laboratory testing services throughout Vietnam. Based on test type, the market is segmented into:

• Immunoassay-Based Diagnostic Tests
• Molecular Diagnostic Tests
• Clinical Chemistry Tests
• Hematology Tests
• Microbiology & Culture-Based Tests
• Coagulation Tests
• Others

Infectious Diseases Remain the Largest Diagnostic Testing Application Segment

Infectious diseases accounted for an estimated 32.0% share of the Vietnam Diagnostic Tests Market in 2026, making it the largest disease application segment. The dominance is supported by Vietnam’s continued burden of communicable diseases and extensive national screening programs. According to the WHO Global Tuberculosis Report 2024, Vietnam remained among the 30 high-burden TB countries globally. In addition, hepatitis B affects nearly 8–10% of the population, generating sustained demand for communicable disease testing across hospitals, laboratories, and public health facilities.

The segment also benefits from ongoing disease surveillance and outbreak-control activities. According to Vietnam’s Ministry of Health, the country reported more than 76,000 cases of hand, foot, and mouth disease in 2024, while dengue fever continues to require large-scale monitoring during seasonal outbreaks. These public health challenges necessitate continuous screening, confirmatory testing, and epidemiological monitoring to support timely intervention. As a result, demand for pathogen detection solutions and public health screening programs continues to increase, reinforcing the segment’s leadership within the Vietnam diagnostic tests market. Based on disease application type, the industry is segmented into:

• Infectious Diseases
• Oncology
• Cardiovascular Diseases
• Diabetes & Metabolic Disorders
• Women's Health & Reproductive Health
• Autoimmune & Neurological Disorders
• Others

Vietnam Diagnostic Tests Market Competitive Analysis

The Vietnam Diagnostic Tests Market is moderately fragmented, with the top five companies, including Roche Vietnam Company Limited, Siemens Healthcare Limited Company, Abbott Laboratories GmbH (Vietnam), Becton, Dickinson and Company (BD Vietnam), and Thermo Fisher Scientific (Vietnam), accounting for approximately 39% of the total market share in 2026. These companies are actively investing in laboratory automation, molecular diagnostics, immunoassay platforms, and digital healthcare technologies to strengthen their market position and expand diagnostic capabilities across Vietnam.

Top Companies in the Vietnam Diagnostic Tests Market

• Roche Vietnam Company Limited
• Siemens Healthcare Limited Company
• Abbott Laboratories GmbH (Vietnam)
• Becton, Dickinson and Company (BD Vietnam)
• Thermo Fisher Scientific (Vietnam)
• Bio-Rad Laboratories, Inc.
• Medtronic Vietnam Company Limited
• Viet A Corporation
• Medicon JSC
• Sao Thai Duong JSC

Vietnam Diagnostic Tests Industry News and Recent Developments

August 2025: First NAEOTOM Alpha Deployment Supports Advanced Disease Detection in Vietnam

The installation of Siemens Healthineers' NAEOTOM Alpha system at Phuong Dong General Hospital marked a significant enhancement in Vietnam's diagnostic capabilities, particularly for oncology, cardiology, and neurology applications. While primarily an imaging advancement, the technology strengthens the country's broader diagnostic ecosystem by enabling earlier and more precise disease identification.

Impact Analysis: The deployment supports Vietnam's transition toward precision diagnostics and encourages healthcare providers to invest in advanced disease detection technologies, complementing growth in laboratory and diagnostic testing services.

December 2025: Bach Mai Hospital Introduces Photon-Counting CT Technology in Vietnam's Public Healthcare System

Bach Mai Hospital became the first public hospital in Vietnam to deploy two NAEOTOM Alpha photon-counting CT systems, expanding access to advanced diagnostic technologies within the country's public healthcare infrastructure. The installation represents one of the most significant healthcare technology upgrades in Vietnam's public sector.

Impact Analysis: The deployment enhances diagnostic capabilities for complex diseases and supports broader healthcare modernization efforts. Improved disease detection rates are expected to increase downstream demand for confirmatory laboratory testing, pathology services, and precision diagnostic solutions.